Compare Entegris Inc (ENTG) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Summit Therapeutics Inc — how do they compare? Entegris Inc trades at $134.28 (market cap $21.12B), while Summit Therapeutics Inc trades at $13.97 (market cap $11.70B). The key difference: Entegris Inc is the larger of the two by market cap, and Entegris Inc pays a 0.29% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ENTG | SMMT | |
|---|---|---|
Market Cap | $21.12B | $11.70B |
Sector | Technology | Health |
52-Week High | $184.00 | $29.32 |
52-Week Low | $68.80 | $13.05 |
Enterprise Value | $24.44B | $11.12B |
Dividend Yield | 0.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $134.15, down 4.61% today, with technical indicators showing bearish momentum as the stock approaches key support at $133. The company maintains solid fundamentals with Q1 2026 earnings beating estimates at $0.86 per share and strong analyst consensus of 65% buy ratings. Recent developments include a $0.10 dividend declaration and new CFO appointment, while semiconductor industry tailwinds from AI-driven demand provide growth catalysts.
ENTG presents a compelling opportunity with 25% upside to the $178.40 consensus price target, supported by improving cash flow trends and semiconductor sector growth. However, elevated valuation multiples (P/E 80.17) and technical bearish signals warrant caution amid recent price volatility and competitive pressures in the semiconductor materials space.
Summit Therapeutics (SMMT) trades at $14.51, down 6.21% today, with a bearish technical outlook despite positive clinical trial results for its lung cancer drug ivonescimab. The company reported a net loss of $1.08 billion in 2025, with negative ROE and ROA, but maintains strong analyst support with 14 buy ratings and a $15.57 consensus price target. Recent developments include the $105 million divestiture of ridinilazole to Biossil and upcoming Q2 2026 earnings.
SMMT presents a high-risk, binary investment case centered on ivonescimab's commercial potential. While analyst sentiment is bullish and recent trial data is promising, the company's significant losses, cash burn, and single-asset focus pose substantial risks. The stock's volatility and concentrated ownership create potential for sharp moves around clinical and regulatory catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
